Scinai Immunotherapeutics (SCNI) Accumulated Expenses (2021 - 2025)

Scinai Immunotherapeutics has disclosed Accumulated Expenses across 5 years of filings, most recently posting $441000.0 for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $441000.0, up 73.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $441000.0 (up 73.62% YoY), and the FY2025 annual result was $441000.0, up 73.62% from the prior year.
• Accumulated Expenses came in at $441000.0 for Q4 2025 at Scinai Immunotherapeutics, up from $254000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $756000.0 in Q4 2022 to a low of $254000.0 in Q4 2024.
• The 5-year median for Accumulated Expenses is $441000.0 (2025), against an average of $454600.0.
• Across the five-year window, Accumulated Expenses surged 109.42% in 2022 and tumbled 44.9% in 2024, its largest moves.
• Scinai Immunotherapeutics' Accumulated Expenses stood at $361000.0 in 2021, then soared by 109.42% to $756000.0 in 2022, then slumped by 39.02% to $461000.0 in 2023, then sank by 44.9% to $254000.0 in 2024, then surged by 73.62% to $441000.0 in 2025.
• The last three Accumulated Expenses figures came in at $441000.0 (Q4 2025), $254000.0 (Q4 2024), and $461000.0 (Q4 2023), per Business Quant data.